Bausch + Lomb Corporation’s acquisition of XIIDRA, a non-steroid eye drop approved for treating dry eye disease, has cleared the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act. The waiting period expired on August 23, 2023. The acquisition is expected to be completed by the end of September, pending the fulfillment of remaining customary closing conditions.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (the “HSR Act”), with respect to the previously announced agreement to acquire XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
Expiration of the HSR Act waiting period occurred at 11:59 p.m. ET on Aug. 23, 2023. Completion of the transaction is expected to occur at or around the end of September, subject to satisfaction of the remaining customary closing conditions.
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.